BioCentury | Dec 28, 2019
Financial News

Elpiscience’s $100M series B provides path to IPO

Elpiscience hopes a $100 million series B round led by Hyfinity Investments will enable the company to expand its immuno-oncology pipeline and provide enough runway to carry it to an IPO, Ming Fang, head of...
BioCentury | Dec 4, 2018
Financial News

Hillhouse backs Elpiscience's $35M round

Elpiscience Biopharma Ltd. (Shanghai, China) raised $35 million in a series A+ round led by Hillhouse Capital Management. Existing investor Lilly Asia Ventures and CDH Investments also participated in the round. Elpiscience is stocking its...
BioCentury | Apr 26, 2018
Product R&D

Brake for gas

Elpiscience Biopharmaceuticals Co. Ltd. has emerged from stealth mode with an unconventional bispecific that simultaneously removes the brakes and steps on the gas for antitumor immunity, but only inside tumors. The goal is to upstage...
Items per page:
1 - 3 of 3